89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, announced inducement grants for two new employees. The Compensation Committee approved non-qualified stock options to purchase 32,350 shares of common stock on July 2, 2025.
The grants, made under the company's 2023 Inducement Plan, will vest over four years, with 25% vesting after one year and the remainder vesting in 12 quarterly installments. The exercise price equals the closing price of 89bio's stock on the grant date.
89bio (Nasdaq: ETNB), un'azienda biofarmaceutica in fase clinica specializzata in terapie per malattie epatiche e cardiometaboliche, ha annunciato concessioni di incentivi per due nuovi dipendenti. Il Comitato per la Remunerazione ha approvato opzioni azionarie non qualificate per l'acquisto di 32.350 azioni ordinarie con scadenza il 2 luglio 2025.
Le concessioni, effettuate nell'ambito del Piano di Incentivazione 2023 dell'azienda, matureranno in un periodo di quattro anni, con il 25% che matura dopo un anno e il restante che matura in 12 rate trimestrali. Il prezzo di esercizio corrisponde al prezzo di chiusura delle azioni di 89bio alla data di concessione.
89bio (Nasdaq: ETNB), una compañía biofarmacéutica en etapa clínica especializada en terapias para enfermedades hepáticas y cardiometabólicas, anunció concesiones de incentivos para dos nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones no calificadas para comprar 32,350 acciones ordinarias con vencimiento el 2 de julio de 2025.
Las concesiones, realizadas bajo el Plan de Incentivos 2023 de la empresa, se consolidarán durante cuatro años, con un 25% consolidado después de un año y el resto consolidado en 12 cuotas trimestrales. El precio de ejercicio es igual al precio de cierre de las acciones de 89bio en la fecha de concesión.
89bio (나스닥: ETNB)는 간 및 심장대사 질환 치료제에 특화된 임상 단계의 바이오제약 회사로, 두 명의 신입 직원에 대한 유인 주식 옵션 부여를 발표했습니다. 보상 위원회는 2025년 7월 2일에 만료되는 32,350주의 보통주를 구매할 수 있는 비자격 주식 옵션을 승인했습니다.
이 부여는 회사의 2023년 유인 계획에 따라 이루어졌으며, 4년에 걸쳐 권리가 취득되며 1년 후 25%가 취득되고 나머지는 12분기 분할로 취득됩니다. 행사가격은 부여일의 89bio 주식 종가와 동일합니다.
89bio (Nasdaq : ETNB), une société biopharmaceutique en phase clinique spécialisée dans les thérapies pour les maladies du foie et cardiométaboliques, a annoncé l'attribution d'actions incitatives à deux nouveaux employés. Le comité de rémunération a approuvé des options d'achat d'actions non qualifiées pour acquérir 32 350 actions ordinaires, exerçables jusqu'au 2 juillet 2025.
Les attributions, effectuées dans le cadre du plan d'incitation 2023 de la société, seront acquises sur une période de quatre ans, avec 25 % acquis après un an et le reste acquis par 12 versements trimestriels. Le prix d'exercice correspond au cours de clôture de l'action 89bio à la date d'attribution.
89bio (Nasdaq: ETNB), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Therapien für Leber- und kardiometabolische Erkrankungen spezialisiert hat, gab Anreizzuteilungen für zwei neue Mitarbeiter bekannt. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 32.350 Aktien Stammaktien mit Ablaufdatum 2. Juli 2025.
Die Zuteilungen, die im Rahmen des Inducement-Plans 2023 des Unternehmens erfolgen, werden über vier Jahre vesten, wobei 25 % nach einem Jahr vesten und der Rest in 12 vierteljährlichen Raten. Der Ausübungspreis entspricht dem Schlusskurs der 89bio-Aktie am Zuteilungsdatum.
- None.
- None.
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,350 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on July 2, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
What stock options did 89bio (ETNB) grant to new employees in July 2025?
What is the vesting schedule for 89bio's July 2025 inducement grants?
Why did 89bio (ETNB) issue inducement grants in July 2025?
What is 89bio's (ETNB) main business focus?
